AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...

The stock's fall snapped a two-day winning streak.

AbbVie Inc.’s TV advertisements featuring tennis legend Serena Williams make misleading claims about the effectiveness of its ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $196.42 which represents a slight increase of $3.02 or 1.56% from the prior close of $193.4. The stock opened at $194.97 and touched a ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

As with many other companies AbbVie Inc. (NYSE:ABBV) makes use of debt. But should shareholders be worried about its use of debt? Debt is a tool to help businesses grow, but if a business is incapable ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...